TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7946917

Group type: EXPERIMENTAL
Intervention: Fluid and salt supplementation (FSS) during hypokinesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hypokinetic subjects (no FSS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects (10,000 running steps/d)
Number of subjects: 30
Study: 3368545

Group type: EXPERIMENTAL
Intervention: Low-dose neuroleptics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose neuroleptics (excluding relapsed patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative family attitudes (measured at study entry)
Number of subjects: 0
Study: 31124218

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, 20 min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: SHAM (placebo)
Number of subjects: 18
Study: 28290958

Group type: EXPERIMENTAL
Intervention: Practical training
Number of subjects: 285

Group type: COMPARATOR
Intervention: Instruction video
Number of subjects: 285

Group type: COMPARATOR
Intervention: Theoretical lecture
Number of subjects: 285
Study: 26211873

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) to the right temporal pole (RTP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) to the left temporal pole (LTP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group with rTMS delivered to the vertex
Number of subjects: 20
Study: 22906162

Group type: EXPERIMENTAL
Intervention: Romiplostim 750 μg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 21519749

Group type: EXPERIMENTAL
Intervention: Flaxseed powder (60 g/day, 10 g ALA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isocaloric roasted cassava powder (60 g/day, fat-free)
Number of subjects: 16
Study: 18050063

Group type: EXPERIMENTAL
Intervention: Medium tempi music
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fast tempi music
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mixed tempi music
Number of subjects: 29

Group type: COMPARATOR
Intervention: No-music control
Number of subjects: 29
Study: 16005478

Group type: EXPERIMENTAL
Intervention: Individuals with WS rating of happy faces as approachable
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individuals with WS rating of less approachable face stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls rating of happy faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls rating of less approachable face stimuli
Number of subjects: 0
Study: 12929758

Group type: EXPERIMENTAL
Intervention: Exposure to a mental rotation task (adapted Cube Comparison test)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Detailed instructions
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 113
Study: 10638870

Group type: EXPERIMENTAL
Intervention: Portable 3-D scanner
Number of subjects: 23

Group type: COMPARATOR
Intervention: Multipurpose 2-D real-time scanner
Number of subjects: 23
Study: 9113580

Group type: EXPERIMENTAL
Intervention: Temporal approach phacoemulsification
Number of subjects: 80

Group type: COMPARATOR
Intervention: Superior approach phacoemulsification
Number of subjects: 80
Study: 7691775

Group type: EXPERIMENTAL
Intervention: Grid laser treatment (low energy scatter photocoagulation applied to areas of presumed CNV and abnormal retinal pigment epithelium, sparing the fovea)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Natural course (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Grid laser treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Grid laser treatment and Natural course (control group)
Number of subjects: 24
Study: 3531036

Group type: EXPERIMENTAL
Intervention: Dipyridamole plus aspirin
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study: 30037621

Group type: EXPERIMENTAL
Intervention: Sound intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27941937

Group type: EXPERIMENTAL
Intervention: Pegylated-interferon-alpha-2b monotherapy or combination therapy with adefovir dipivoxil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pegylated-interferon-alpha-2b
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NKp30+ NK cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-15
Number of subjects: 0
Study: 24323035

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/d continuously plus prednisone 5 mg twice daily
Number of subjects: 873

Group type: COMPARATOR
Intervention: Placebo plus prednisone 5 mg twice daily
Number of subjects: 873
Study: 22112424

Group type: EXPERIMENTAL
Intervention: Brief Intervention for Socially Anxious Drinkers (BISAD)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Alcohol psychoeducation
Number of subjects: 41
Study: 20230604

Group type: EXPERIMENTAL
Intervention: Triple P, level 3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 19001962

Group type: EXPERIMENTAL
Intervention: High FFP:PRBC ratio (≥1:1.5, n ≤ 102)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Low FFP:PRBC ratio (<1:1.5, n ≤ 313)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: High FFP:PRBC ratio (≥1:1.5)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Low FFP:PRBC ratio (<1:1.5)
Number of subjects: 415
Study: 15545978

Group type: EXPERIMENTAL
Intervention: NRG1 haplotypes and markers
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: NRG1 transcript expression in peripheral leukocytes
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Correlation of NRG1 variants
Number of subjects: 111
Study: 12860491

Group type: EXPERIMENTAL
Intervention: Simvastatin (40-80 mg)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20-80 mg)
Number of subjects: 212
Study: 10547243

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (1 x 10(10) - 2 x 10(10) CFU per day)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 202
Study: 8905602

Group type: EXPERIMENTAL
Intervention: Oral oestradiol
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 7506866

Group type: EXPERIMENTAL
Intervention: Cefotiam 4 g a day for 7 days (arm A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tosufloxacin 300 mg a day for 7 days (arm B)
Number of subjects: 150
Study: 2885368

Group type: EXPERIMENTAL
Intervention: Ultrasound detector (UD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Clinical rating (CR) scale
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal subjects (control)
Number of subjects: 46
Study: 29040226

Group type: EXPERIMENTAL
Intervention: Oxandrolone and propranolol (Oxprop)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 27404645

Group type: EXPERIMENTAL
Intervention: Stage of change
Number of subjects: 3213

Group type: EXPERIMENTAL
Intervention: Effort
Number of subjects: 3213

Group type: EXPERIMENTAL
Intervention: Severity (sun severity)
Number of subjects: 3213

Group type: EXPERIMENTAL
Intervention: Severity (smoking severity)
Number of subjects: 3213
Study: 26243795

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 9140

Group type: COMPARATOR
Intervention: Untreated patients (Control)
Number of subjects: 9140
Study: 23579893

Group type: EXPERIMENTAL
Intervention: Xeno V
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Clearfil S(3) Bond
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: G-Bond
Number of subjects: 48
Study: 20463100

Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg daily) plus placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (100 microg) plus placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) and calcium
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Calcium load (600 mg of calcium carbonate)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (100 microg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 99
Study: 18771766

Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Laparoscopic-Assisted Vaginal Hysterectomy (LAVH)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Minilaparotomy Hysterectomy (MiniLPT)
Number of subjects: 150
Study: 16636233

Group type: EXPERIMENTAL
Intervention: Hematoma growth
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Percentage hematoma growth
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Initial ICH volume
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Score (GCS)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Intraventricular hemorrhage (IVH)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Percentage growth
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 218
Study: 12816288

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with anti-infective therapy (metronidazole gel, chlorhexidine gluconate 0.2%, doxycycline 100 mg x 1/day for 6 to 8 weeks, ibuprofen 3 x 400 mg/day for 7 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR) without anti-infective therapy (chlorhexidine gluconate 0.2% for 1 week, doxycycline 100 mg x 1/day for 1 week, ibuprofen 3 x 400 mg/day for 7 days)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Comparison of new tissue growth at retrieval
Number of subjects: 38
Study: 10519578

Group type: EXPERIMENTAL
Intervention: Intracameral 1% unpreserved lidocaine combined with topical anesthesia (oxybuprocaine)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Peribulbar anesthesia with 6 ml prilocaine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intracameral 1% unpreserved lidocaine
Number of subjects: 200
Study: 7661884

Group type: EXPERIMENTAL
Intervention: LDL subclass pattern B
Number of subjects: 92

Group type: COMPARATOR
Intervention: LDL subclass pattern A
Number of subjects: 92
Study: 2477130

Group type: EXPERIMENTAL
Intervention: Cibenzoline (130 to 160 mg bid)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cibenzoline (130 to 160 mg bid) in phase 2
Number of subjects: 18
Study: 1261197

Group type: EXPERIMENTAL
Intervention: 3 fractions of radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7 fractions of radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 fractions of radiation
Number of subjects: 0
Study: 30571546

Group type: EXPERIMENTAL
Intervention: 2 mg 17β‐estradiol per day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2+2 mg 17β‐estradiol per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy age‐matched young women)
Number of subjects: 20
Study: 28363007

Group type: EXPERIMENTAL
Intervention: Genotypes 'CNFC 10762', 'IAC Dawn', and 'BRS Style'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster analysis using Euclidean distance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yield grain character
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hybrids with high heterotic effect
Number of subjects: 0
Study: 27063130

Group type: EXPERIMENTAL
Intervention: Damon high torque appliances
Number of subjects: 40

Group type: COMPARATOR
Intervention: MBT straight wire appliance
Number of subjects: 40
Study: 24002519

Group type: EXPERIMENTAL
Intervention: CONNECT intervention (centralized, nurse-delivered telephone-based service)
Number of subjects: 775
Study: 21709093

Group type: EXPERIMENTAL
Intervention: Finafloxacin (up to 800 mg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Finafloxacin (400 mg and above)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Finafloxacin
Number of subjects: 95
Study: 19590021

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 149
Study: 16289608

Group type: EXPERIMENTAL
Intervention: Effortful processing (disengagement from supraliminal dysphoric pictures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automatic processing (disengagement from masked pictures depicting threat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stressful challenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 15329112

Group type: EXPERIMENTAL
Intervention: sustained-release alfuzosin 5 mg twice daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 81
Study: 11144370

Group type: EXPERIMENTAL
Intervention: Hexavac
Number of subjects: 848

Group type: COMPARATOR
Intervention: Pentavac and H-B-Vax II
Number of subjects: 848

Group type: COMPARATOR
Intervention: Pentavac
Number of subjects: 848

Group type: COMPARATOR
Intervention: H-B-Vax II
Number of subjects: 848
Study: 9333329

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 10% (200/0.5) at 12 ml per kg body-weight daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 7936015

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 3330989

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 0
Study: 31362799

Group type: EXPERIMENTAL
Intervention: Thinking Healthy Programme Peer-delivered (THPP)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 850
Study: 29076400

Group type: EXPERIMENTAL
Intervention: Sleep condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Total sleep deprivation
Number of subjects: 40
Study: 30017258

Group type: EXPERIMENTAL
Intervention: Physical therapy interventions
Number of subjects: 616
Study: 28058714

Group type: EXPERIMENTAL
Intervention: Myo‐inositol 1000 mg, Tribulus Terrestris 300 mg, Alga Ecklonia Bicyclis 200 mg and Biovis one tablet a day for 90 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo tablet a day for 90 days
Number of subjects: 60
Study: 26759291

Group type: EXPERIMENTAL
Intervention: Bio‐Oss Collagen and Bio‐Gide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (spontaneous healing)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Micro‐computed tomography results
Number of subjects: 16
Study: 24490577

Group type: EXPERIMENTAL
Intervention: Jiangzhikangyanghua mixture 20 mL tid + amlodipine 5 mg qd + valsartan 80 mg qd
Number of subjects: 72

Group type: COMPARATOR
Intervention: Amlodipine 5 mg qd + valsartan 80 mg qd
Number of subjects: 72
Study: 21328025

Group type: EXPERIMENTAL
Intervention: G-CSF (1.5 μg/kg) injected for 14 consecutive days
Number of subjects: 40
Study: 18294600

Group type: EXPERIMENTAL
Intervention: Living dog (Dog)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robotic dog (AIBO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no AAT)
Number of subjects: 0
Study: 16782490

Group type: EXPERIMENTAL
Intervention: Delayed clamping (2 min after delivery of the infant's shoulders)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Early clamping (around 10 s after delivery)
Number of subjects: 476
Study: 15272957

Group type: EXPERIMENTAL
Intervention: Proximity to an overweight woman
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Proximity to heavy individuals
Number of subjects: 2
Study: 10999555

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 300 mg/d
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 46
Study: 8979144

Group type: EXPERIMENTAL
Intervention: Relapse of nephrotic syndrome
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Remission of nephrotic syndrome
Number of subjects: 89

Group type: COMPARATOR
Intervention: Healthy age- and sex-matched controls
Number of subjects: 89
Study: 1361964

Group type: EXPERIMENTAL
Intervention: 50 micrograms GHRH
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 50 micrograms SRIF
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 6823952

Group type: EXPERIMENTAL
Intervention: Vita‐Stat automatic blood pressure recorder
Number of subjects: 408

Group type: COMPARATOR
Intervention: Random-Zero sphygmomanometer
Number of subjects: 408
Study: 30656993

Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g every 6 hours)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 30316488

Group type: EXPERIMENTAL
Intervention: Web-based therapist-assisted acceptance-based behavioral intervention (Surviving and Thriving During Stress)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 26867802

Group type: EXPERIMENTAL
Intervention: Yoga (YG)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Stretching (ST)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 163
Study: 25251999

Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim 25 µg/kg (body-weight-adjusted)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim 50 or 100 μg/kg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim 6 mg (fixed-dose)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Pegfilgrastim 100 μg/kg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Pegfilgrastim 6 mg (fixed-dose)
Number of subjects: 89
Study: 21675542

Group type: EXPERIMENTAL
Intervention: Emotion-focused self-regulation strategies (e.g., comfort seeking)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Planful self-regulation strategies (e.g., distraction)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Trajectory analysis of emotional SRS
Number of subjects: 117
Study: 19532850

Group type: EXPERIMENTAL
Intervention: Tramadol/acetaminophen and naloxone infusion (0.25 microg/kg/h for 48 hours)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tramadol/acetaminophen and naloxone infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard therapy (historical controls)
Number of subjects: 10
Study: 16765847

Group type: EXPERIMENTAL
Intervention: Sesame oil (SO) 5 ml by mouth at bedtime
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo 5 ml by mouth at bedtime
Number of subjects: 107
Study: 15325416

Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine 5 mg/kg body weight
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11216930

Group type: EXPERIMENTAL
Intervention: Isoniazid (H) for 6 months
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Rifampicin plus pyrazinamide (RZ) for 3 months
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Tuberculosis (associated with mortality)
Number of subjects: 1053
Study: 9257377

Group type: EXPERIMENTAL
Intervention: Topical retinol preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin E cream
Number of subjects: 0
Study: 8382234

Group type: EXPERIMENTAL
Intervention: Amlodipine (231 patients, 5-10 mg/day)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Enalapril (230 patients, 10-40 mg/day)
Number of subjects: 461
Study: 3791659

Group type: EXPERIMENTAL
Intervention: Ethanol ingestion (1.5 ml/kg initial dose, maintained at 110-140 mg%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control day (no ethanol ingestion)
Number of subjects: 8
Study: 1124370

Group type: EXPERIMENTAL
Intervention: Proximal selective vagotomy with pyloroplasty
Number of subjects: 35

Group type: COMPARATOR
Intervention: Proximal selective vagotomy without pyloroplasty
Number of subjects: 35
Study: 31898656

Group type: EXPERIMENTAL
Intervention: Interdigitated HDRICBT with EBRT 50 Gy/25 fractions and 8 Gy/fraction weekly for three fractions
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sequential HDRICBT with EBRT 50 Gy/25 fractions and 8 Gy/fraction weekly for three fractions
Number of subjects: 82
Study: 28804455

Group type: EXPERIMENTAL
Intervention: Cathode placed on left DLPFC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cathode placed on shoulder
Number of subjects: 0
Study: 25332169

Group type: EXPERIMENTAL
Intervention: Single session of rTMS (n = 19)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ten sessions of low-frequency rTMS (n = 15)
Number of subjects: 34
Study: 23136031

Group type: EXPERIMENTAL
Intervention: Dual blockade of ACEI and ARB (subgroup AA)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Lowered dialysate sodium concentration from 140 mmol/l to 138 mmol/l
Number of subjects: 148

Group type: COMPARATOR
Intervention: ACEI (subgroup A)
Number of subjects: 148
Study: 21640057

Group type: EXPERIMENTAL
Intervention: Teledentistry examination
Number of subjects: 234

Group type: COMPARATOR
Intervention: Traditional visual/tactile oral examination
Number of subjects: 234
Study: 19996424

Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone-artesunate (CDA) 2.0/2.5/4.0 mg/kg, once daily for 3 days
Number of subjects: 892

Group type: COMPARATOR
Intervention: Chlorproguanil-dapsone (CPG-DDS) 2.0/2.5 mg/kg, once daily for 3 days
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: CDA in G6PD-deficient patients
Number of subjects: 892

Group type: COMPARATOR
Intervention: CPG-DDS in G6PD-deficient patients
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: CDA in G6PD-normal patients
Number of subjects: 892

Group type: COMPARATOR
Intervention: CPG-DDS in G6PD-normal patients
Number of subjects: 892
Study: 16997506

Group type: EXPERIMENTAL
Intervention: Radiotherapy-related typing
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Zhi-guang Xie typing system
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: 1992 Fuzhou staging system
Number of subjects: 842
Study: 15534546

Group type: EXPERIMENTAL
Intervention: Rotating platform tibia group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Modular metal-backed group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: All-polyethylene group
Number of subjects: 240

Group type: COMPARATOR
Intervention: Posterior-stabilized, fixed-bearing knee (control)
Number of subjects: 240
Study: 11333852

Group type: EXPERIMENTAL
Intervention: Home-based dietary treatment with locally available foods and micronutrient supplements
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 141